Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$855 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.8
Industry P/E
--
EV/EBITDA
-12
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.8
Face value
--
Shares outstanding
62,028,100
CFO
$-76.19 Mln
EBITDA
$-94.47 Mln
Net Profit
$-52.69 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
GH Research PLC (GHRS)
| 82.3 | 22.9 | 12.4 | 6.3 | 6.9 | -- | -- |
|
BSE Sensex
| 3.7 | -1.6 | 9.6 | 5.9 | 14.3 | 19.1 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
GH Research PLC (GHRS)
| -40.3 | -58.3 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
GH Research PLC (GHRS)
|
12.8 | 855.4 | 0.0 | -42.1 | -- | -16.9 | -- | 2.8 |
| 29.8 | 5,075.7 | 1,513.8 | 352.7 | 27.3 | 25.2 | 14.7 | 3.3 | |
| 1.0 | 39.6 | 0.0 | -22.6 | -- | -- | -- | 6.0 | |
| 5.1 | 274.5 | 137.9 | -110.3 | -101.1 | -22.7 | -- | 0.6 |
GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is... in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland. Address: Joshua Dawson House, Dublin, Ireland, D02 RY95 Read more
Co-Founder & Non-Executive Chairman of the Board
Mr. Florian Schonharting M.Sc. (Econ)
Co-Founder & Non-Executive Chairman of the Board
Mr. Florian Schonharting M.Sc. (Econ)
Headquarters
Dublin
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of GH Research PLC (GHRS) stood at $ 330 Mln as on 31-Mar-25
The share price of GH Research PLC (GHRS) is $12.76 (NASDAQ) as of 13-Jun-2025 16:00 EDT. GH Research PLC (GHRS) has given a return of 6.88% in the last 3 years.
GH Research PLC (GHRS) has a market capitalisation of $ 855 Mln as on 12-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of GH Research PLC (GHRS) is 2.76 times as on 12-Jun-2025, a 0% premium to its peers’ median range of 2.76 times.
Since, TTM earnings of GH Research PLC (GHRS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the GH Research PLC (GHRS) and enter the required number of quantities and click on buy to purchase the shares of GH Research PLC (GHRS).
GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland. Address: Joshua Dawson House, Dublin, Ireland, D02 RY95
The CEO & director of Mr. Florian Schonharting M.Sc. (Econ). is GH Research PLC (GHRS), and CFO & Sr. VP is Mr. Florian Schonharting M.Sc. (Econ).
There is no promoter pledging in GH Research PLC (GHRS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
501
|
|
|
76
|
|
|
5
|
|
|
501
|
|
|
76
|
|
|
5
|
| GH Research PLC (GHRS) | Ratios |
|---|---|
|
Return on equity(%)
|
-16.86
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of GH Research PLC (GHRS) was $0 Mln.
$-0.07
(
